Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

Inclusion Criteria Parts 1 and 2: * ≥18 to 65 years old at time of informed consent * HLA-A\*02:01 positive * Documented evidence of CHB based on one of the following: a. Positive HBsAg and HBV DNA at least 6 months prior to the Screening visit; OR b. Historical liver biopsy consistent with CHB infection. * Have been receiving entecavir and/or tenofovir (including tenofovir alafenamide) for ≥12months prior to screening and are willing to continue. * HBV DNA negative at screening * No history of liver cirrhosis AND prior assessment of fibrosis demonstrating non-cirrhotic status at screening * Participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the trial screening date until 3 months after the final dose of the study intervention or longer if required by local regulations Part 3: * ≥18 years old at time of informed consent * HLA-A\*02:01 positive * ECOG ≤1 * Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology / cytology, or clinically by American Association for the Study of Liver Diseases criteria * Failed or intolerant of ≥1 systemic therapy * At least one measurable lesion (per RECIST 1.1) which is either not previously treated or, if treated, has clearly progressed prior to enrollment * Documented evidence of CHB based on one of the following: a. Positive HBsAg and HBV DNA at least 6 months prior to the Screening visit; OR b.…